Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth B Gordon

Showing results (51-60 of 136) with videos related to

Pageof 14
Sort By:
Journal of the American Academy of Dermatology|December 15, 2010
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Archives of Dermatology|June 20, 2007
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasisStephen Tyring, Kenneth B Gordon, Yves Poulin, et al.
The Journal of Dermatological Treatment|March 17, 2007
Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activityAmir A Toor, Patrick J Stiff, Brian J Nickoloff, et al.
Journal of the American Academy of Dermatology|November 23, 2006
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasisAngela Moore, Kenneth B Gordon, Sewon Kang, et al.
The American Journal of Cardiology|April 9, 2008
The editor's roundtable: psoriasis, inflammation, and coronary artery diseaseVincent E Friedewald, Jennifer C Cather, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasisKim A Papp, Bruce Miller, Kenneth B Gordon, et al.
The Journal of Dermatological Treatment|February 10, 2006
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapyKenneth B Gordon, Alice B Gottlieb, Craig L Leonardi, et al.
Journal of Drugs in Dermatology : JDD|December 31, 2004
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasisAlice B Gottlieb, Kenneth B Gordon, Mark G Lebwohl, et al.
Seminars in Cutaneous Medicine and Surgery|July 18, 2018
Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology SeminarHilary E Baldwin, Linda F Stein Gold, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|September 23, 2014
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisKenneth B Gordon, Craig L Leonardi, Mark Lebwohl, et al.
Pageof 14

Showing results (51-60 of 136) with videos related to

Sort By:
Pageof 14
Journal of the American Academy of Dermatology|December 15, 2010
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Archives of Dermatology|June 20, 2007
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasisStephen Tyring, Kenneth B Gordon, Yves Poulin, et al.
The Journal of Dermatological Treatment|March 17, 2007
Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activityAmir A Toor, Patrick J Stiff, Brian J Nickoloff, et al.
Journal of the American Academy of Dermatology|November 23, 2006
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasisAngela Moore, Kenneth B Gordon, Sewon Kang, et al.
The American Journal of Cardiology|April 9, 2008
The editor's roundtable: psoriasis, inflammation, and coronary artery diseaseVincent E Friedewald, Jennifer C Cather, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasisKim A Papp, Bruce Miller, Kenneth B Gordon, et al.
The Journal of Dermatological Treatment|February 10, 2006
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapyKenneth B Gordon, Alice B Gottlieb, Craig L Leonardi, et al.
Journal of Drugs in Dermatology : JDD|December 31, 2004
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasisAlice B Gottlieb, Kenneth B Gordon, Mark G Lebwohl, et al.
Seminars in Cutaneous Medicine and Surgery|July 18, 2018
Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology SeminarHilary E Baldwin, Linda F Stein Gold, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|September 23, 2014
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisKenneth B Gordon, Craig L Leonardi, Mark Lebwohl, et al.
Pageof 14